A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Myotonic Dystrophy Type 1 (DM1)
Спонсор: Vertex Pharmaceuticals Incorporated
Налично на:
БГ
Обобщение
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Кой може да участва
Key Inclusion Criteria:
• Completed study drug treatment in parent study VX23-670-001 (NCT06185764)
Key Exclusion Criteria:
• History of any illness or any clinical condition as pre-specified in the protocol
Other protocol defined Inclusion/Exclusion criteria may apply.
БГ
EN